Dimerization of a PACAP peptide analogue in DMSO via asparagine and aspartic acid residues

Journal of Pharmaceutical Sciences

Volumn 97, Issue 3, 2008, Pages 1246-1256

  Severs, Joanne C ^a   Froland, Wayne A ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Deamidation; Dehydration; Formulation; HPLC (high performance pressure liquid chromatography); Mass spectrometry; Peptide delivery; Peptides; Physical characterization; Physical stability; Stability

Indexed keywords

ASPARAGINE; ASPARTIC ACID; DIMETHYL SULFOXIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

AQUEOUS SOLUTION; ARTICLE; DEAMINATION; DIMERIZATION; DRUG FORMULATION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HYDROLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVERSED PHASE LIQUID CHROMATOGRAPHY; AMINO ACID SEQUENCE; CHEMISTRY; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ASPARAGINE; ASPARTIC ACID; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; DIMETHYL SULFOXIDE; MOLECULAR SEQUENCE DATA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 42949173525     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21116     Document Type: Article

References (22)

1. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev 52:269-324.
2. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, Hamren S, Livingston JN, Pan CQ. 2002. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal A potential therapy for type 2 diabetes. Diabetes 51: 1453-1460.
3. Yung SL, Cruz FD, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M, Roczniak S, Todd T, Lemoine L, MacDougall M, Shanafelt AB, Pan CQ. 2003. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem 278: 10273-10281.
4. Pan C, Li F, Tom I, Wang W, Dumas M, Froland W, Yung SL, Li Y, Roczniak S, Claus TH, Wang YJ, Whelan JP. 2007. Engineering novel VPAC2 selective agonists with improved stability and glucose lowering activity in vivo. J Pharmacol Exp Ther 330:900-906.
5. Wang W, Martin-Moe S, Pan C, Musza L, Wang JY. 2007. Stabilization of a polypeptide in non-aqueous solvents. Int J Pharm (submitted for publication).
6. Capasso S, Mazzarella L, Zagari A. 1991. Deamidation via cyclic imide of asparaginyl peptides: Dependence on salts, buffers and organic solvents. Pept Res 4:234-238.
7. Brennan TV, Clark S. 1993. Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric. Prot Sci 2:331-338.
8. Li R, D'Souza AJ, Laird BB, Schowen RL, Borchardt RT, Topp EM. 2000. Effects of solution polarity and viscosity on peptide deamidation. J Pept Res 56: 326-334.
9. Smyth DG, Stein WH, Moore S. 1962. On the sequence of residues 11 to 18 in bovine pancreatic ribonuclease. J Biol Chem 237:1845-1850.
10. Teshima G, Stults JT, Ling V, Canova-Davis E. 1991. Isolation and characterization of a succinimide variant of methionyl human growth hormone. J Biol Chem 266:13544-13547.
11. Tsuda T, Uchiyama M, Sato T, Yoshino H, Tsuchiya Y, lshikawa S, Ohmae M, Watanabe S, Miyake Y. 1990. Mechanism and kinetics of secretin degradation in aqueous solutions. J Pharm Sci 79:223-227.
12. Aswad D. 1995. Deamidation and isoaspartate formation in peptides and proteins Boca Raton: CRC Press.
13. Radkiewicz JL, Zipse H, Clarke S, Houk KN. 2001. Neighboring side chain effects on asparaginyl and aspartyl degradation: An ab initio study of the relationship between peptide conformation and backbone NH acidity. J Am Chem Soc 123:3499-3506.
14. Wary V, Kakoschke C, Nokihara K, Naruse S. 1993. Solution structure of pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry 32:5832-5841.
15. Stephenson RC, Clarke S. 1989. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem 264:6164-6170.
16. 129. Prot Sci 1:1634-1641.
17. Oliyai C, Borchardt RT. 1993. Chemical pathways of peptide degradation IV. Pathways, kinetics and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res 10:95-102.
18. Darrington RT, Anderson BD. 1995. Effects of insulin concentration and self-association on the partitioning of its A21 cyclic anhydride intermediate to desamido insulin and covalent dimer. Pharm Res 12:1077-1084.
19. Strickley RG, Anderson BD. 1996. Solid-state stability of human insulin I. Mechanism and the effect of water on the kinetics of degradation in lyophiles from pH2-5 solutions. Pharm Res 13: 1142-1152.
20. Hefford MA, Kaplan H. 1989. Chemical properties of the histidine residue of secretin: Evidence for a specific intramolecular interaction. Biochim Bio-phys Acta 998:267-270.
21. Goossens JF, Cotelle P, Chavatte P, Henichart JP. 1996. NMR study of five N-terminal peptide fragments of the vasoactive intestinal peptide: Crucial role of aromatic residues. Pept Res 9:322-326.
22. 2+ binding properties of secretin. Biochemistry 37:16967-16974.